Other featured articles
COVID-19’s Total Cost to the U.S. Economy Will Reach $14 Trillion by End of 2023
Workplace absences, along with sales lost due to the cessation of brick-and-mortar retail shopping, airline travel and public gatherings, contributed the most.Posted in
The Agency Keeping Alzheimer’s Drugs From Patients
The Centers for Medicare and Medicaid Services refuses to approve breakthrough drugs.Posted in
A Strategy for Value-Based Drug Pricing Under the Inflation Reduction Act
To make sure that CMS is getting its money’s worth for today’s drugs, it must ensure that the maximum fair price is aligned to drug value.Posted in
A COVID Takeaway for California: Data Needs to Drive Health Policy
A key lesson from the pandemic is that the state needs to get a better handle on economic trade-offs as it implements preventive measures, especially vaccines.Posted in
Medicare’s ‘Coverage with Evidence Development’: A Barrier to Patient Access and Innovation
CMS should abandon CED or, at minimum, reform and restrict its use only for off-label applications of therapies.
Alternatives To The QALY For Comparative Effectiveness Research
We now have useful and valid alternatives that allow for the assessment and valuation of treatments that improve population health without discriminating against vulnerable patient populations.
Comments to CMS on the Inflation Reduction Act’s Drug Price Negotiation Program
Over 20 researchers cosigned a comment letter to Centers for Medicaid and Medicare Services providing recommendations for the Medicare Drug Price Negotiation Program
Ending Health Insurance for Generic Drugs Would Save Patients Money
Eliminating insurance for generics might make patients nervous at first, but the payoff would be stable and affordable prices.
Should the Government Restrict Direct-to-Consumer Prescription Drug Advertising? Six Takeaways on their Effects.
Policymakers should proceed with caution as they design proposals to restrict advertising.